Cancer Communications
indexed by SCI
BMC

doi: 10.1186/s40880-017-0179-6
Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review
Aurélien Simon, Hampig Raphael Kourie and Joseph Kerger
Jules Bordet Institute, Free University of Brussels
[Abstract] Metastatic melanoma has long been considered to have a very poor prognosis and to be chemo-resistant. However, a subgroup of patients with metastatic melanoma presents remarkable responses to chemotherapeutic agents, even in the absence of a response to modern targeted therapies and immunotherapies; accordingly, determining predictive biomarkers of the response to chemotherapies for metastatic melanoma remains a priority to guide treatment in these patients. We report a case study of a patient with B-Raf proto-oncogene serine/threonine kinase-mutated metastatic melanoma harbouring many genetic mutations. The patient did not respond to prior targeted therapies or immunotherapies but experienced a dramatic objective radiological and clinical response to subsequent dacarbazine-based chemotherapy. In the era of targeted therapies and immunotherapies for metastatic melanoma, cytotoxic chemotherapies may still represent an interesting therapeutic weapon in a well-defined subgroup of patients presenting with specific genetic and molecular features.
Chinese Journal of Cancer 2017, Volume: 36, Issue 4
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)

[Google Scholar]


Cite this article

Aurélien Simon, Hampig Raphael Kourie and Joseph Kerger. Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review. Chin J Cancer. 2017, 36:10. doi:10.1186/s40880-017-0179-6


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CC Wechat 微信公众号

 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China